-
公开(公告)号:US20190241676A1
公开(公告)日:2019-08-08
申请号:US16256737
申请日:2019-01-24
发明人: Sohail Tavazoie , Nils Halberg , Masoud Tavazoie
IPC分类号: C07K16/40 , A61K31/138 , A61K31/475 , A61K31/404 , A61K31/44 , A61K39/395 , C07K16/00 , C07K16/28 , C07K16/30 , A61K31/4535 , A61K31/436 , A61P35/00 , A61K45/06 , A61K31/675 , A61K31/655 , A61K31/513 , A61K31/337
CPC分类号: C07K16/40 , A61K31/138 , A61K31/337 , A61K31/404 , A61K31/436 , A61K31/44 , A61K31/4535 , A61K31/475 , A61K31/513 , A61K31/655 , A61K31/675 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61P35/00 , C07K16/00 , C07K16/2863 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要: The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.
-
公开(公告)号:US20190231907A1
公开(公告)日:2019-08-01
申请号:US16373803
申请日:2019-04-03
申请人: Duke University
IPC分类号: A61K49/10 , A61K47/54 , A61K49/08 , A61P35/00 , A61K31/675 , A61K31/663 , A61K9/00
CPC分类号: A61K49/101 , A61K9/0019 , A61K31/663 , A61K31/675 , A61K47/548 , A61K49/06 , A61K49/085 , A61K49/103 , A61K49/106 , A61P35/00
摘要: Provided herein are magnetic resonance imaging (MRI) contrast agents comprising a compound having a structure represented by: Y—X—Z, wherein, X is: Fe(III) or Mn(II), and Y and Z are each independently selected from pyrophosphate and bisphosphonate (e.g., 1-hydroxybisphosphonate), or a pharmaceutically acceptable hydrate and/or salt thereof. Methods of use of the MRI contrast agent are also provided.
-
公开(公告)号:US20190183912A1
公开(公告)日:2019-06-20
申请号:US16327631
申请日:2017-08-22
发明人: Daniel Da Costa , Cyril B. Dousson , David Dukhan , Jean-Laurent Paparin , Houcine Rahali , Izzat Raheem
IPC分类号: A61K31/675 , A61P31/12
CPC分类号: A61K31/675 , A61K45/05 , A61K45/06 , A61P31/00 , A61P31/12 , C07F9/65616
摘要: Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
-
公开(公告)号:US20190100541A1
公开(公告)日:2019-04-04
申请号:US16208083
申请日:2018-12-03
申请人: MEDIVIR AB
发明人: Richard BETHELL , Anders ENEROTH , Bjorn KLASSON , Fredrik OBERG
IPC分类号: C07F9/6558 , A61K45/06 , C07D405/04 , A61K31/675
CPC分类号: C07F9/65586 , A61K31/506 , A61K31/675 , A61K45/06 , C07D405/04 , C07F9/24
摘要: The invention provides compounds of the formula: R1 is OR11, or NR5R5′; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(═O)R6, O(C═O)R6 or O(OQ)OR6; R5′ is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.
-
公开(公告)号:US20180353523A1
公开(公告)日:2018-12-13
申请号:US15761914
申请日:2016-09-21
申请人: Viking Therapeutics
发明人: Brian Lian
IPC分类号: A61K31/675 , A61P3/00 , A61K31/155
CPC分类号: A61K31/675 , A61K31/155 , A61K31/4188 , A61K31/506 , A61K45/06 , A61K2300/00 , A61P3/00 , C07F9/65586
摘要: The present invention provides pharmaceutical compositions and methods for treating and/or preventing a metabolic condition.
-
公开(公告)号:US20180353485A1
公开(公告)日:2018-12-13
申请号:US15546149
申请日:2016-01-25
发明人: Junya Toguchida , Makoto Ikeya , Akira Ohta , Kyosuke Hino
IPC分类号: A61K31/436 , A61P19/08 , A61K31/675
CPC分类号: A61K31/436 , A61K31/675 , A61P19/08
摘要: The present invention relates to a prophylactic or therapeutic agent for fibrodysplasia ossificans progressiva comprising as an active ingredient, at least one compound selected from the group consisting of rapamycin, temsirolimus, everolimus, ridaforolimus, TAFA93, umirolimus, olcorolimus, zotarolimus, and pharmaceutically acceptable salts thereof.
-
公开(公告)号:US20180334490A1
公开(公告)日:2018-11-22
申请号:US15529246
申请日:2015-12-02
申请人: Jennifer Brogdon , Gregory Beatty , David Glass , Carl H. June , Joan Mannick , Michael Milone , Leon Murphy , Gabriela Plesa , Huijuan Song , Qilong Wu , Novartis AG , The Trustees of the University of Pennsylvania
发明人: Jennifer Brogdon , Gregory Beatty , David Glass , Carl H. June , Joan Mannick , Michael Milone , Leon Murphy , Gabriela Plesa , Huijuan Song , Qilong Wu
IPC分类号: C07K14/725 , A61P35/00 , A61K35/17 , C07K14/705 , C07K16/28 , C07K16/30 , A61K45/06 , A61K38/17 , A61K39/395 , A61K31/675 , A61K31/436 , A61N5/10
CPC分类号: C07K14/7051 , A61K31/436 , A61K31/675 , A61K35/00 , A61K35/17 , A61K38/177 , A61K38/1774 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/5256 , A61K2039/545 , A61N5/10 , A61N2005/1098 , A61P35/00 , C07K14/70521 , C07K14/70578 , C07K16/28 , C07K16/2803 , C07K16/2863 , C07K16/30 , C07K16/3023 , C07K16/303 , C07K16/3061 , C07K16/3069 , C07K2317/24 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C07K2319/70
摘要: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to the methods of preconditioning a subject, e.g., by depleting B cells in combination with the use of a cell comprising a chimeric antigen receptor (CAR) that targets a tumor antigen as described herein. The methods for preconditioning the subject described herein include using a cell comprising a CAR that targets a B cell antigen as described herein.
-
8.
公开(公告)号:US20180327495A1
公开(公告)日:2018-11-15
申请号:US16041399
申请日:2018-07-20
申请人: Immunomedics, Inc.
IPC分类号: C07K16/28 , A61K31/337 , A61K39/395 , A61K31/502 , A61K31/519 , A61K31/4745 , A61K31/52 , A61P35/00 , A61K31/357 , A61K45/06 , A61K31/4184 , A61K31/4375 , A61K31/454 , A61K31/513 , A61K31/675 , A61K31/7088 , A61K31/713 , A61K33/24 , C07K16/30 , A61K47/68
CPC分类号: A61K47/6853 , A61K31/337 , A61K31/357 , A61K31/4184 , A61K31/4375 , A61K31/454 , A61K31/4745 , A61K31/502 , A61K31/513 , A61K31/519 , A61K31/52 , A61K31/675 , A61K31/7088 , A61K31/713 , A61K33/24 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K47/6851 , A61K2039/505 , A61P35/00 , C07K16/2803 , C07K16/2833 , C07K16/2887 , C07K16/30 , C07K16/3007 , C07K2317/24 , C07K2317/92 , C07K2317/94 , A61K2300/00
摘要: The present invention relates to combination therapy with drugs, such as Bruton's tyrosine kinase inhibitors or PI3K inhibitors, with antibodies or ADCs against HLA-DR. Where ADCs are used, they preferably incorporate SN-38 or pro-2PDOX. The ADC may be administered at a dosage of between 1 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the combination therapy has an additive effect on inhibiting tumor growth. Most preferably, the combination therapy has a synergistic effect on inhibiting tumor growth.
-
公开(公告)号:US20180305380A1
公开(公告)日:2018-10-25
申请号:US16022977
申请日:2018-06-29
IPC分类号: C07F5/02 , A61K31/69 , A61K31/198 , C07C233/83 , A61K31/675 , C07F5/05 , A61K31/454
CPC分类号: C07F5/025 , A61K31/198 , A61K31/454 , A61K31/675 , A61K31/69 , C07C233/83 , C07F5/05 , A61K2300/00
摘要: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
-
公开(公告)号:US20180303856A1
公开(公告)日:2018-10-25
申请号:US16025199
申请日:2018-07-02
发明人: K. Raja Reddy , Jeff Stebbins , Serge H. Boyer , Mark D. Erion , Scott J. Hecker , Nicholas Brian Raffaele , Brett C. Bookser , Venkat Reddy Mali
IPC分类号: A61K31/675 , A61K31/542 , A61K31/52 , A61K31/688 , A61K31/683 , A61P3/10 , C07F9/40 , C07F9/655 , C07F9/48 , A61P3/04 , A61K31/662 , A61K31/665 , A61K45/06 , C07D473/16 , C07D473/34 , C07D473/40 , C07F9/30 , C07F9/6574 , C07F9/6561 , C07F9/653 , C07F9/32
CPC分类号: A61K31/675 , A61K31/52 , A61K31/542 , A61K31/662 , A61K31/665 , A61K31/683 , A61K31/688 , A61K45/06 , A61P3/04 , A61P3/10 , C07D473/16 , C07D473/34 , C07D473/40 , C07F9/303 , C07F9/3229 , C07F9/40 , C07F9/48 , C07F9/65312 , C07F9/6552 , C07F9/6561 , C07F9/65616 , C07F9/65742 , A61K2300/00
摘要: This invention pertains to the use of fused bicycle heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.
-
-
-
-
-
-
-
-
-